Business Update

Chugai Pharmaceutical concludes co-promotion agreement for Pletaal

Published in Cardiovascular Business Week, January 9th, 2007

Otsuka Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. announced the conclusion of a co-promotion agreement for the antiplatelet agent Pletaal (nonproprietary name: cilostazol) in the Japanese hemodialysis market.

Pletaal has been solely distributed by Otsuka Pharmaceutical in Japan since April 1988.

Under the agreement, Chugai will start co-promotion activities for Pletaal in the hemodialysis market in March 2007.

Pletaal is an antiplatelet agent with a platelet aggregation inhibitory action and a vasodilating action developed by Otsuka Pharmaceutical. Indicated for improvement of ischemic symptoms including ulcer,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2007-01-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry